Welcome to our dedicated page for VEXT SCIENCE news (Ticker: VEXTF), a resource for investors and traders seeking the latest updates and insights on VEXT SCIENCE stock.
Vext Science, Inc. (VEXTF) is a U.S.-based cannabis operator with vertical operations in Arizona and Ohio, specializing in cultivation, manufacturing, and retail of high-quality cannabis products. The company owns and operates cutting-edge cultivation and manufacturing facilities, alongside dispensaries, offering a range of award-winning products like Vapen™. Known for its commitment to quality and profitability, Vext's leadership team focuses on delivering a superior customer experience while driving shareholder value.
Rhea-AI Summary
Vext Science, Inc. announces new date for Q4 and fiscal 2023 financial results release. The company will release its financial results for the period ended December 31, 2023, on May 10, 2024, and host a conference call and webcast on the same day at 1:00 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.47%
Tags
-
Rhea-AI Summary
Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF) announces a delay in the filing of its annual financial statements for 2023, related management discussions, and officer certifications. The delay is due to a recent auditor change and complex accounting treatment of Q4 2023 transactions. The company has postponed its conference call scheduled for April 25, 2024, until the filings are complete. Vext is actively working with auditors to complete the filings by May 10, 2024, and has applied for a management cease trade order to restrict trading until filings are submitted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.82%
Tags
-
Rhea-AI Summary
Vext Science, Inc. (VEXTF) to announce financial results for Q4 and Fiscal 2023 on April 25, 2024. The U.S.-based cannabis operator with operations in Arizona and Ohio will host a conference call to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.62%
Tags
Rhea-AI Summary
Vext Science, Inc. completes the acquisition of real property associated with a cannabis dispensary in Athens, Ohio as part of the Ohio Expansion Transaction. The Company paid $2.6 million for the acquisition, with $0.9 million in cash and a $1.7 million promissory note at 7.0% interest repayable over 10 years. The acquisition is expected to be completed by the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
-
Rhea-AI Summary
Vext Science, Inc. changes its auditor from BF Borgers CPA PC to Reliant CPA due to enforcement actions by the Canadian Public Accountability Board. The Former Auditor resigned, and the Successor Auditor was appointed effective March 8, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
-
Rhea-AI Summary
Vext Science, Inc. receives regulatory approval and closes debenture conversion transaction. Insider shareholder Sopica Special Opportunities Fund Limited acquires 24,087,500 common shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
Rhea-AI Summary
Vext Science, Inc. completes the acquisition of a cannabis dispensary in Columbus, Ohio, positioning itself for growth in the $4 billion Ohio market. The company pays approximately $3 million for the Columbus Dispensary, enhancing its vertical operations in the state.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
-
Rhea-AI Summary
Vext Science, Inc. has entered into an agreement with Zuanic & Associates to participate in US cannabis industry panels, aiming to raise public awareness of the company. The initial term of the agreement is six months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
-
Rhea-AI Summary
Vext Science, Inc. announces the transition of Jason Thai Nguyen from his executive positions with the company while remaining on the board of directors. The settlement agreement details the extended payment period for Mr. Nguyen's cash severance amount. Additionally, an amendment to the promissory note, and a shareholders agreement with certain management shareholders and other shareholders of the company has been made.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
Rhea-AI Summary
Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF) announced the addition of Terry L. Creighton and Spiro A. Phanos to its Board of Directors. Shareholders voted in favor of all matters at the annual general meeting, with each resolution passing with over 96% of the votes cast. The new directors bring leadership capabilities, operating experience, and deep expertise from the pharmaceutical and financial sectors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.98%
Tags
FAQ
What is the current stock price of VEXT SCIENCE (VEXTF)?
The current stock price of VEXT SCIENCE (VEXTF) is $0.129 as of November 22, 2024.
What is the market cap of VEXT SCIENCE (VEXTF)?
The market cap of VEXT SCIENCE (VEXTF) is approximately 34.1M.
What is Vext Science, Inc. known for?
Vext Science, Inc. is renowned for its vertical operations in Arizona and Ohio, specializing in cultivation, manufacturing, and retail of high-quality cannabis products.
Where does Vext Science, Inc. operate?
Vext Science, Inc. is based in the U.S., with key operations in Arizona and Ohio, where they own and operate state-of-the-art cultivation facilities, manufacturing plants, and dispensaries.
What products does Vext Science, Inc. offer?
Vext Science, Inc. offers a variety of products, including award-winning THC concentrates, edibles, and distillate cartridges under the brand Vapen™. These products are known for their quality and popularity in Arizona and Ohio.
How does Vext Science, Inc. differentiate itself?
Vext Science, Inc. distinguishes itself through its focus on profitability, quality, and customer experience. The company's leadership team is dedicated to delivering value to shareholders while maintaining a strong presence in the cannabis market.
What is Vext Science, Inc.'s stock symbol?
Vext Science, Inc. is listed on the Canadian Securities Exchange under the symbol VEXT and trades on the OTCQX market under the symbol VEXTF.
VEXT SCIENCE INC
OTC:VEXTF
VEXTF Rankings
VEXTF Stock Data
34.05M
61.23M
45.8%
0.36%
Drug Manufacturers - Specialty & Generic
Healthcare
United States of America
Phoenix